September 15, 2025 a 05:01 pm
ABT: Analysts Ratings - Abbott Laboratories
Abbott Laboratories, a global leader in healthcare products, has demonstrated resilience through its diverse segments in pharmaceuticals, diagnostics, nutrition, and medical devices. Recent analyst ratings provide a positive yet cautious outlook, reflecting on slight market volatility and steady performance in core areas.
Historical Stock Grades
Recent data on Abbott Laboratories shows a stable yet cautious market sentiment, with a majority of analysts leaning towards Buy or Strong Buy recommendations. This underlines a generally positive outlook, albeit with some reservations as seen with Hold and a few Strong Sell ratings.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 6 | |
| Buy | 14 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
- Ratings data over recent months indicate a slight decline in Strong Buy recommendations coupled with a steady increase in Hold ratings, suggesting a cautious optimism among analysts.
- While Buy ratings remain predominant, the shift towards more conservative ratings highlights market uncertainties possibly influenced by economic conditions or company-specific developments.
- The total number of evaluations has remained stable, suggesting continued interest and scrutiny from the analyst community.
Percentage Trends
Comparative analysis over time reveals a gradual shift from aggressive to more conservative ratings. There's a noticeable decrease in Strong Buy percentages and a concurrent rise in Hold recommendations.
- Strong Buy: Dropped from 25% to 21%.
- Buy: Maintained an average of around 50%-60%.
- Hold: Increased from 15% to 25%.
Over the last year, the most significant change is the modest decline of Strong Buy opinions, complemented by an increase in Hold ratings, reflecting a more cautious market outlook.
Latest Analyst Recommendations
The latest analyst actions reveal a steady outlook with minimal changes in strong buy or hold positions. This indicates confidence in Abbott's performance but also highlights awareness of potential risks linked to the broader market conditions.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-09-10 | Outperform | Outperform | Bernstein |
| 2025-07-18 | Buy | Buy | Citigroup |
| 2025-07-18 | Outperform | Outperform | Raymond James |
| 2025-07-18 | Neutral | Neutral | Mizuho |
| 2025-07-18 | Buy | Buy | BTIG |
Analyst Recommendations with Change of Opinion
Recent changes in analyst opinions are indicative of shifting perspectives. While some analysts have upgraded Abbott, other recommendations remain consistent, highlighting a balanced view of the company's future prospects.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-18 | Buy | Hold | Jefferies |
| 2023-07-21 | Peer Perform | Underperform | Wolfe Research |
| 2023-07-20 | Peer Perform | Underperform | Wolfe Research |
| 2021-10-27 | Overweight | Neutral | Atlantic Equities |
| 2021-10-26 | Overweight | Neutral | Atlantic Equities |
Interpretation
The prevailing market sentiment for Abbott Laboratories suggests moderate confidence amidst varying economic scenarios. Analysts maintain a generally optimistic stance with continued Buy and Strong Buy ratings. However, the rise in Hold recommendations indicates caution regarding future volatility. The stability in analyst sentiment may either reinforce confidence or reveal underlying concerns about market dynamics.
Conclusion
Abbott Laboratories appears well-positioned in the healthcare market with diverse operational segments. The mix of optimistic and cautious ratings reflects its strong market standing, tempered by economic uncertainties. Investors can expect steady performance, with potential growth in diagnostic and device segments. The balance of recommendations suggests cautious optimism, highlighting the need for close monitoring of macroeconomic trends affecting Abbott's operations.